Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
Public ClinicalTrials.gov record NCT00819052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to demonstrate the efficacy of nevirapine extended release (NVP XR) based regimen for HIV-1 infected patients who were receiving nevirapine immediate release (NVP IR) based regimen for at least 18 prior weeks of therapy.
Study identification
- NCT ID
- NCT00819052
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 445 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2008 (Type not available)
- Primary completion
- Jan 2012 (Actual)
- Completion
- Jan 2012 (Actual)
- Last update posted
- Nov 10, 2014
2008 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1100.1526.1012 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1100.1526.1014 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1100.1526.1011 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1100.1526.1013 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1100.1526.1001 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 1100.1526.1004 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 1100.1526.1006 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1100.1526.1002 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1100.1526.1005 Boehringer Ingelheim Investigational Site | Miami Beach | Florida | — | — |
| 1100.1526.1003 Boehringer Ingelheim Investigational Site | Berkley | Michigan | — | — |
| 1100.1526.1007 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00819052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 10, 2014 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00819052 live on ClinicalTrials.gov.